Page 604 - Read Online

Page 24 of 26 Ralph et al. J Cancer Metastasis Treat 2018;4:49 I http://dx.doi.org/10.20517/2394-4722.2018.42

celecoxib plus difluoromethylornithine in patients with familial adenomatous polyposis. Gut 2016;65:286-95.
103. Burn J, Sheth H. The role of aspirin in preventing colorectal cancer. Br Med Bull 2016;119:17-24.
104. Emilsson L, Holme Ø, Bretthauer M, Cook NR, Buring JE, Løberg M, Adami HO, Sesso HD, Gaziano MJ, Kalager M. Systematic review
with meta-analysis: the comparative effectiveness of aspirin vs. screening for colorectal cancer prevention. Aliment Pharmacol Ther
2017;45:193-204.
105. Paleari L, Puntoni M, Clavarezza M, DeCensi M, Cuzick J, DeCensi A. PIK3CA mutation, aspirin use after diagnosis and survival of
colorectal cancer. A systematic review and meta-analysis of epidemiological studies. Clin Oncol (R Coll Radiol) 2016;28:317-26.
106. Liao X, Lochhead P, Nishihara R, Morikawa T, Kuchiba A, Yamauchi M, Imamura Y, Qian ZR, Baba Y, Shima K, Sun R, Nosho K,
Meyerhardt JA, Giovannucci E, Fuchs CS, Chan AT, Ogino S. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl
J Med 2012;367:1596-606.
107. Alfonso L, Ai G, Spitale RC, Bhat GJ. Molecular targets of aspirin and cancer prevention. Br J Cancer 2014;111:61-7.
108. Dunlap T, Piyankarage SC, Wijewickrama GT, Abdul-Hay S, Vanni M, Litosh V, Luo J, Thatcher GR. Quinone-induced activation of
Keap1/Nrf2 signaling by aspirin prodrugs masquerading as nitric oxide. Chem Res Toxicol 2012;25:2725-36.
109. Jian Z, Tang L, Yi X, Liu B, Zhang Q, Zhu G, Wang G, Gao T, Li C. Aspirin induces Nrf2-mediated transcriptional activation of haem
oxygenase-1 in protection of human melanocytes from H2 O2 -induced oxidative stress. J Cell Mol Med 2016;20:1307-18.
110. Satoh T, Lipton S. Recent advances in understanding NRF2 as a druggable target: development of pro-electrophilic and non-covalent NRF2
activators to overcome systemic side effects of electrophilic drugs like dimethyl fumarate. F1000Res 2017;6:2138.
111. Hua X, Phipps AI, Burnett-Hartman AN, Adams SV, Hardikar S, Cohen SA, Kocarnik JM, Ahnen DJ, Lindor NM, Baron JA, Newcomb
PA. Timing of aspirin and other nonsteroidal anti-inflammatory drug use among patients with colorectal cancer in relation to tumor markers
and survival. J Clin Oncol 2017;35:2806-13.
112. Kuo CN, Pan JJ, Huang YW, Tsai HJ, Chang WC. Association between nonsteroidal anti-inflammatory drugs and colorectal cancer: a
population-based case-control study. Cancer Epidemiol Biomarkers Prev 2018;27:737-45.
113. Elwood PC, Morgan G, Pickering JE, Galante J, Weightman AL, Morris D, Kelson M, Dolwani S. Aspirin in the treatment of cancer:
reductions in metastatic spread and in mortality: a systematic review and meta-analyses of published studies. PLoS One 2016;11:e0152402.
114. Chubak J, Whitlock EP, Williams SB, Kamineni A, Burda BU, Buist DS, Anderson ML. Aspirin for the prevention of cancer incidence and
mortality: systematic evidence reviews for the U.S. preventive services task force. Ann Intern Med 2016;164:814-25.
115. Huang XZ, Chen Y, Wu J, Zhang X, Wu CC, Zhang CY, Sun SS, Chen WJ. Aspirin and non-steroidal anti-inflammatory drugs use reduce
gastric cancer risk: a dose-response meta-analysis. Oncotarget 2017;8:4781-95.
116. Li P, Wu H, Zhang H, Shi Y, Xu J, Ye Y, Xia D, Yang J, Cai J, Wu Y. Aspirin use after diagnosis but not prediagnosis improves established
colorectal cancer survival: a meta-analysis. Gut 2015;64:1419-25.
117. Usman MW, Luo F, Cheng H, Zhao JJ, Liu P. Chemopreventive effects of aspirin at a glance. Biochim Biophys Acta 2015;1855:254-63.
118. Veettil SK, Lim KG, Ching SM, Saokaew S, Phisalprapa P, Chaiyakunapruk N. Effects of aspirin and non-aspirin nonsteroidal anti-
inflammatory drugs on the incidence of recurrent colorectal adenomas: a systematic review with meta-analysis and trial sequential analysis
of randomized clinical trials. BMC Cancer 2017;17:763.
119. Johnson CC, Jankowski M, Rolnick S, Yood MU, Alford SH. Influence of NSAID use among colorectal cancer survivors on cancer
outcomes. Am J Clin Oncol 2017;40:370-4.
120. Zhao X, Xu Z, Li H. NSAIDs use and reduced metastasis in cancer patients: results from a meta-analysis. Sci Rep 2017;7:1875.
121. Moris D, Kontos M, Spartalis E, Fentiman IS. The role of NSAIDs in breast cancer prevention and relapse: current evidence and future
perspectives. Breast Care (Basel) 2016;11:339-44.
122. Veitonmäki T, Murtola TJ, Talala K, Taari K, Tammela T, Auvinen A. Non-steroidal anti-inflammatory drugs and cancer death in the finnish
prostate cancer screening trial. PLoS One 2016;11:e0153413.
123. Zhou CK, Daugherty SE, Liao LM, Freedman ND, Abnet CC, Pfeiffer R, Cook MB. Do aspirin and other NSAIDs confer a survival benefit
in men diagnosed with prostate cancer? A pooled analysis of NIH-AARP and PLCO cohorts. Cancer Prev Res (Phila) 2017;10:410-20.
124. Rachidi S, Wallace K, Li H, Lautenschlaeger T, Li Z. Postdiagnosis aspirin use and overall survival in patients with melanoma. J Am Acad
Dermatol 2018;78:949-56.
125. van Staalduinen J, Frouws M, Reimers M, Bastiaannet E, van Herk-Sukel MP, Lemmens V, de Steur WO, Hartgrink HH, van de Velde CJ,
Liefers GJ. The effect of aspirin and nonsteroidal anti-inflammatory drug use after diagnosis on survival of oesophageal cancer patients. Br
J Cancer 2016;114:1053-9.
126. Frouws MA, Bastiaannet E, Langley RE, Chia WK, van Herk-Sukel MP, Lemmens VE, Putter H, Hartgrink HH, Bonsing BA, Van de Velde
CJ, Portielje JE, Liefers GJ. Effect of low-dose aspirin use on survival of patients with gastrointestinal malignancies; an observational study.
Br J Cancer 2017;116:405-13.
127. Matsuo K, Cahoon SS, Yoshihara K, Shida M, Kakuda M, Adachi S, Moeini A, Machida H, Garcia-Sayre J, Ueda Y, Enomoto T, Mikami M,
Roman LD, Sood AK. Association of low-dose aspirin and survival of women with endometrial cancer. Obstet Gynecol 2016;128:127-37.
128. Zhang D, Bai B, Xi Y, Zhao Y. Can aspirin reduce the risk of endometrial cancer? A systematic review and meta-analysis of observational
studies. Int J Gynecol Cancer 2016;26:1111-20.
129. Spence AD, Busby J, Johnston BT, Baron JA, Hughes CM, Coleman HG, Cardwell CR. Low-dose aspirin use does not increase survival in
2 independent population-based cohorts of patients with esophageal or gastric cancer. Gastroenterology 2018;154:849-60.
130. Dixon SC, Nagle CM, Wentzensen N, Trabert B, Beeghly-Fadiel A, Schildkraut JM, Moysich KB, deFazio A; Australian Ovarian Cancer
Study Group, Risch HA, Rossing MA, Doherty JA, Wicklund KG, Goodman MT, Modugno F, Ness RB, Edwards RP, Jensen A, Kjær SK,
Høgdall E, Berchuck A, Cramer DW, Terry KL, Poole EM, Bandera EV, Paddock LE, Anton-Culver H, Ziogas A, Menon U, Gayther SA,
Ramus SJ, Gentry-Maharaj A, Pearce CL, Wu AH, Pike MC, Webb PM. Use of common analgesic medications and ovarian cancer survival:
results from a pooled analysis in the Ovarian Cancer Association Consortium. Br J Cancer 2017;116:1223-8.
131. Brasky TM, Felix AS, Cohn DE, McMeekin DS, Mutch DG, Creasman WT, Thaker PH, Walker JL, Moore RG, Lele SB, Guntupalli SR,